JNJ 26481585 dihydrochloride - Quisinostat dihydrochloride

Based on 92 publications in PubMed 9 10 92

Axon 2529

CAS [875320-31-3]

MF C21H26N6O2.2HCl
MW 467.39

  • Purity: 99%
  • Soluble in DMSO

JNJ 26481585 dihydrochloride

Description

Potent, orally available second-generation pan-HDAC inhibitor (highest IC50 value 0.11 nM for HDAC1, and sub-nanomolar for HDAC2, HDAC4, HDAC10, and HDAC11 in vitro) with activity in human leukemia. JNJ-26481585 induces continuous acetylation of histone H3, activation of the caspase cascade, and upregulation of p21, resulting in apoptosis and cell cycle arrest in the myeloma cells at low nanomolar concentrations. JNJ26481585 also potently induced tubulin acetylation.

KEYWORDS: JNJ 26481585 HCl | supplier | HDAC inhibitor | Quisinostat dihydrochloride | JNJ26481585 | CAS [875320-31-3] | [875320-29-9] | Histone | HDAC | Inhibitor | HDAC1 | HDAC2 | HDAC4 | HDAC10 | HDAC11 | tubulin | epigenetic | apoptosis | leukemia | acetylation

Order
Size Unit Price Stock
5 mg €125.00 In Stock
25 mg €435.00 In Stock
Special Offers
Size Unit Price Stock
2 x 5 mg €180.00 In Stock
2 x 25 mg €640.00 In Stock
Need more? Bulk Inquiry

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...